2021
The impact and collateral damage of COVID-19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel survey analysis
Surasi DSS, Wang X, Bathala TK, Hwang H, Arora S, Westphalen AC, Chang SD, Turkbey B. The impact and collateral damage of COVID-19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel survey analysis. Abdominal Radiology 2021, 46: 4362-4369. PMID: 33904992, PMCID: PMC8077193, DOI: 10.1007/s00261-021-03087-8.Peer-Reviewed Original ResearchConceptsBowel preparationMedian numberProstate MRICoronavirus disease 2019 (COVID-19) pandemicCOVID-19Disease 2019 pandemicCOVID-19 pandemicHealth care systemComplete responseMedical oncologyProstate biopsyClinic schedulesProstate cancerMRI studiesLockdown periodCare systemCollateral damageRadiation oncologyClinical departmentsPanel survey analysisMRIBiopsyRadiology departmentOncologyDescriptive statisticsMR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer
Galgano SJ, Planz VB, Arora S, Rais-Bahrami S. MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer. Current Urology Reports 2021, 22: 3. PMID: 33403460, DOI: 10.1007/s11934-020-01020-y.Peer-Reviewed Original ResearchConceptsTreatment modalitiesProstate cancerFocal therapyFavorable side effect profileLong-term oncologic outcomesSide effect profileMR-Guided HighNovel treatment modalitiesPromising early resultsProstate cancer diagnosisOncologic outcomesDefinitive treatmentUrinary sphincterNeurovascular bundleRadical prostatectomyActive surveillanceRadiation therapyFocal ablationHeterogeneous diseaseProstate glandReviewThe goalTherapyUltrasound ablationCancer diagnosisProstate MRI
2020
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel
Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Fütterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, Ghai S, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020, 296: 76-84. PMID: 32315265, PMCID: PMC7373346, DOI: 10.1148/radiol.2020190646.Peer-Reviewed Original ResearchConceptsPositive predictive valuePI-RADS scoreProstate cancerPI-RADSGleason scorePredictive valueRetrospective cross-sectional studyHigh-grade prostate cancerObserved positive predictive valueOverall positive predictive valueUntreated prostate cancerProstate MRIInterquartile rangeSignificant prostate cancerProstate Imaging ReportingCross-sectional studyMixed-model logistic regressionProstate cancer diseaseReporting Data SystemMRI lesionsBiopsy resultsActive surveillanceClinical careMRI scansImaging Reporting